The results implied that NR2F1 was independently correlated with unfavorable OS after adjustment for stage, primary therapy outcome, race, age, grade, anatomic neoplasm subdivision, lymphatic and venous invasion, and tumor residual disease (Table 1). This evidence concerns the gene NR2F1 and neoplasm.